According to the latest market report published by Acute Market Reports “Pre-menstrual Syndrome Treatment Market - Growth, Future Prospects, and Competitive Analysis, 2023 - 2030,” the global pre-menstrual syndrome treatment market is expected to reach US$ 5,583.9 Mn by 2030, expanding at a CAGR of 2.0% from 2023 to 2030.
Browse the full report Pre-menstrual Syndrome Treatment Market at https://www.acutemarketreports.com/report/pre-menstrual-syndrome-treatment-market
Market Insights
Pre-menstrual syndrome (PMS) is defined as a condition that affects women at childbearing age and is characterized by symptoms such as bloating, pain, breast tenderness, body pain, fatigue, mood fluctuation, anxiety, etc. where the exact cause of PMS is unknown. According to the American Psychiatric Association, U.S. almost 90% of women of child bearing age experience premenstrual symptoms and less than 10% are diagnosed with premenstrual dysphoric disorder (PMDD). PMDD is a severe and disabling form of PMS affecting 3-8% of women. Some of the therapies used for treatment of pre-menstrual syndrome are changes in diet, home remedies, medications, psychological therapy, supplements and others. Government and non-government agencies’ campaigns towards elevating the status of female health and education has attributed to significant growth in demand for female hygiene products and also PMS treatment drugs. Further growth in female education and the number of working female population will contribute to the demand for PMS drugs in the region.
The global pre-menstrual syndrome treatment market is segmented by drug type as analgesics (pain killers), oral contraceptive pills (OCPs), gonadotropin-releasing hormone (GnRH), antidepressants, ovarian suppressors, diuretics and benzodiazepines. Common painkillers available for treating PMS are NSAIDS and paracetamol. This segment is majorly dominated by over-the-counter drugs that are cheap and easily available in the market
As of the current market scenario, North America and Europe together dominate the pre-menstrual syndrome treatment market due to increase in prevalence of pre-menstrual syndrome and higher awareness about PMS and prevailing treatment options. Asia Pacific, and Middle East and Africa together present lucrative opportunities to manufacturers offering PMS treatment drugs. Large pool of females in childbearing age, growing literacy rate and working population significantly contribute to growing opportunities in the region. Growing number of government initiatives and campaigns focusing on women and maternity health are further driving the market growth.
Market Competition Assessment:
Key players in the global pre-menstrual syndrome treatment market are Alva-Amco Pharmacal Cos., Inc., Bayer, Inc., Chattem, Inc. (Sanofi), DEKK-TEC, Inc., G. R. Lane Health Products Ltd., McNeil Consumer Healthcare, MetP Pharma AG, Pherin Pharmaceuticals, Inc., Umecrine Mood AB, Novartis AG, GlaxoSmithKline Plc and others.
Key Market Movements:
